612832-83-4

Basic information

• Product Name: 2-BENZYLOXY-5-CHLOROPHENYLBORONIC ACID
• Synonyms: 2-BENZYLOXY-5-CHLOROBENZENEBORONIC ACID;2-BENZYLOXY-5-CHLOROPHENYLBORONIC ACID;AKOS BRN-0228;Boronicacid, [5-chloro-2-(phenylmethoxy)phenyl]- (9CI);2-Benzyloxy-5-chlorophenylboronic Acid (contains varying amounts of Anhydride)
• CAS NO: 612832-83-4
• Molecular Formula: C₁₃H₁₂BClO₃
• Molecular Weight: 262.5
• Product Categories: blocks;BoronicAcids
• Mol File: 612832-83-4.mol

Chemical Properties

• Melting Point: 108-110° C
• Boiling Point: 462.3 °C at 760 mmHg
• Flash Point: 233.4 °C
• Appearance: /
• Density: 1.3 g/cm³
• Vapor Pressure: 2.42E-09mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.60±0.53(Predicted)
• CAS DataBase Reference: 2-BENZYLOXY-5-CHLOROPHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYLOXY-5-CHLOROPHENYLBORONIC ACID(612832-83-4)
• EPA Substance Registry System: 2-BENZYLOXY-5-CHLOROPHENYLBORONIC ACID(612832-83-4)

Safety Data

• Hazard Codes: C
• HazardClass: IRRITANT
• Hazardous Substances Data: 612832-83-4(Hazardous Substances Data)

Usage

Uses

suzuki reaction

InChI:InChI=1/C13H12BClO3/c15-11-6-7-13(12(8-11)14(16)17)18-9-10-4-2-1-3-5-10/h1-8,16-17H,9H2

Upstream product

• 106-48-9 4-chloro-phenol 
• 100-39-0 benzyl bromide 
• 7700-27-8 4-chlorophenyl benzyl ether 
• 151038-76-5 1-(benzyloxy)-2-bromo-4-chlorobenzene 
• 695-96-5 2-bromo-4-chlorophenol 
• 100398-25-2 2-benzyloxy-5-chloroiodobenzene 
• 52807-27-9 4-chloro-2-iodo-1-methoxybenzene 
• 71643-66-8 4-chloro-2-iodo phenol 

Downstream Products

• 850913-58-5 2-[2-(benzyloxy)-5-chloro-phenyl]-3-chloro-pyrazine 
• 612833-47-3 1-bromo-2-(2-benzyloxy-5-chlorophenyl)cyclopentene 
• 690259-49-5 (2-benzyloxy-5-chloro[1,1';2',1]terphenyl-3-yl) acetic acid 
• 847148-94-1 3-[2-(benzyloxy)-5-chlorobenzyl]benzonitrile 
• 877383-39-6 4-[[5'-chloro-2'-(phenylmethoxy)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]sulfonyl]morpholine 
• 612832-86-7 3-{2-[5-chloro-2-(benzyloxy)phenyl]cyclopent-1-enyl}benzoic acid ethyl ester 
• 690260-39-0 2-benzyloxy-5-chloro[1,1';2',1]terphenyl-3-carboxylic acid ethyl ester 
• 690259-69-9 5-(2-benzyloxy-5-chloro-[1,1';2',1'']terphenyl-3''-yl)-1H-tetrazole 

Relevant articles and documents

Discovery of GSK345931A: An EP1 receptor antagonist with efficacy in preclinical models of inflammatory pain

Herein we describe the medicinal chemistry programme to identify a potential back-up compound to the EP1 receptor antagonist GW848687X. This work started with the lipophilic 1,2-biaryl benzene derivative 4 which displayed molecular weight of 41

PYRIDYL COMPOUNDS

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein R1, R2, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions compris

BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE

The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Discovery of novel biaryl heterocyclic EP1 receptor antagonists

We describe the generation of novel EP1 receptor antagonists by investigation of thiophene isosteres. In addition, we disclose preliminary in vitro and in vivo DMPK for selected compounds.

2,3-Diarylthiophenes as selective EP1 receptor antagonists

The synthesis and the EP1 receptor binding affinity of 2,3-diarylthiophene derivatives are described. The evaluation of the structure-activity relationship (SAR) in this series led to the identification of compounds 4, 7, and 12a, which exhibit high affinity for the human EP 1 receptor and a selectivity greater than 100-fold against the EP2, EP3, EP4, DP, FP, and IP receptors and greater than 25-fold versus the TP receptor. These three antagonists present good pharmacokinetics in rats and significant differences in the way they are distributed in the brain.

HETEROCYCLYL COMPOUNDS

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, D, Z, R1, R2a , R2b, and Rx are as defined in the specification, a process for the preparation of such compounds, pharm

CYCLOHEXENE COMPOUNDS

Formula (I) wherein A, B, Z, R1, R2a , R2b, R8, R9 and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

NOVEL COMPOUNDS

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation

PHENYL COMPOUNDS

Compounds of formula (I) or derivatives thereof: wherein A, B, Z, R, R, R, R, R, and R are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

(2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: (I) wherein A, R1 , R2 , Rx , R8 , R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.